Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.

TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.

Stephenson RM, Lim CM, Matthews M, Dietsch G, Hershberg R, Ferris RL.

Cancer Immunol Immunother. 2013 Aug;62(8):1347-57. doi: 10.1007/s00262-013-1437-3. Epub 2013 May 18.

PMID:
23685782
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

The therapeutic potential of Toll-like receptor 7 stimulation in asthma.

Drake MG, Kaufman EH, Fryer AD, Jacoby DB.

Inflamm Allergy Drug Targets. 2012 Dec;11(6):484-91. Review.

PMID:
23078048
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy.

Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Saut├Ęs-Fridman C, Tartour E, Zitvogel L, Kroemer G.

Oncoimmunology. 2012 Aug 1;1(5):699-716.

PMID:
22934262
[PubMed]
Free PMC Article
4.

Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies.

Weigel BJ, Cooley S, DeFor T, Weisdorf DJ, Panoskaltsis-Mortari A, Chen W, Blazar BR, Miller JS.

Am J Hematol. 2012 Oct;87(10):953-6. doi: 10.1002/ajh.23280. Epub 2012 Jun 20.

PMID:
22718533
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Toll-Like Receptors (TLRs): The Role in Tumor Progression.

Shcheblyakov DV, Logunov DY, Tukhvatulin AI, Shmarov MM, Naroditsky BS, Gintsburg AL.

Acta Naturae. 2010 Jul;2(3):21-9.

PMID:
22649649
[PubMed]
Free PMC Article
6.

Cancer and innate immune system interactions: translational potentials for cancer immunotherapy.

Liu Y, Zeng G.

J Immunother. 2012 May;35(4):299-308. doi: 10.1097/CJI.0b013e3182518e83. Review.

PMID:
22495387
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Biological characterization of a novel class of toll-like receptor 7 agonists designed to have reduced systemic activity.

Biffen M, Matsui H, Edwards S, Leishman AJ, Eiho K, Holness E, Satterthwaite G, Doyle I, Wada H, Fraser NJ, Hawkins SL, Aoki M, Tomizawa H, Benjamin AD, Takaku H, McInally T, Murray CM.

Br J Pharmacol. 2012 May;166(2):573-86. doi: 10.1111/j.1476-5381.2011.01790.x.

PMID:
22122192
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C.

Jones HM, Chan PL, van der Graaf PH, Webster R.

Br J Clin Pharmacol. 2012 Jan;73(1):77-92. doi: 10.1111/j.1365-2125.2011.04047.x.

PMID:
21689140
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.

Engel AL, Holt GE, Lu H.

Expert Rev Clin Pharmacol. 2011 Mar;4(2):275-89. doi: 10.1586/ecp.11.5. Review.

PMID:
21643519
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers.

Geller MA, Cooley S, Argenta PA, Downs LS, Carson LF, Judson PL, Ghebre R, Weigel B, Panoskaltsis-Mortari A, Curtsinger J, Miller JS.

Cancer Immunol Immunother. 2010 Dec;59(12):1877-84. doi: 10.1007/s00262-010-0914-1. Epub 2010 Sep 5.

PMID:
20820775
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Toll-like receptor agonists: are they good adjuvants?

Gnjatic S, Sawhney NB, Bhardwaj N.

Cancer J. 2010 Jul-Aug;16(4):382-91. doi: 10.1097/PPO.0b013e3181eaca65. Review.

PMID:
20693851
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Toll-like receptor agonists in cancer therapy.

Adams S.

Immunotherapy. 2009 Nov;1(6):949-64. doi: 10.2217/imt.09.70. Review.

PMID:
20563267
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Immune-based therapeutics for pediatric cancer.

Capitini CM, Mackall CL, Wayne AS.

Expert Opin Biol Ther. 2010 Feb;10(2):163-78. doi: 10.1517/14712590903431022. Review.

PMID:
19947897
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality.

Jasperson LK, Bucher C, Panoskaltsis-Mortari A, Mellor AL, Munn DH, Blazar BR.

Blood. 2009 Dec 3;114(24):5062-70. doi: 10.1182/blood-2009-06-227587. Epub 2009 Oct 14.

PMID:
19828695
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment.

Sato Y, Goto Y, Narita N, Hoon DS.

Cancer Microenviron. 2009 Sep;2 Suppl 1:205-14. doi: 10.1007/s12307-009-0022-y. Epub 2009 Aug 15.

PMID:
19685283
[PubMed]
Free PMC Article
16.

Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer.

O'Neill LA, Bryant CE, Doyle SL.

Pharmacol Rev. 2009 Jun;61(2):177-97. doi: 10.1124/pr.109.001073. Epub 2009 May 27. Review.

PMID:
19474110
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting.

Capitini CM, Cooper LJ, Egeler RM, Handgretinger R, Locatelli F, Sondel PM, Mackall CL.

J Pediatr Hematol Oncol. 2009 Apr;31(4):227-44. doi: 10.1097/MPH.0b013e31819a5d8d.

PMID:
19346873
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Comparison of human B cell activation by TLR7 and TLR9 agonists.

Hanten JA, Vasilakos JP, Riter CL, Neys L, Lipson KE, Alkan SS, Birmachu W.

BMC Immunol. 2008 Jul 24;9:39. doi: 10.1186/1471-2172-9-39.

PMID:
18652679
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection.

Taylor PA, Ehrhardt MJ, Lees CJ, Panoskaltsis-Mortari A, Krieg AM, Sharpe AH, Murphy WJ, Serody JS, Hemmi H, Akira S, Levy RB, Blazar BR.

Blood. 2008 Oct 15;112(8):3508-16. doi: 10.1182/blood-2007-09-113670. Epub 2008 Jul 9.

PMID:
18614760
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists.

Birmachu W, Gleason RM, Bulbulian BJ, Riter CL, Vasilakos JP, Lipson KE, Nikolsky Y.

BMC Immunol. 2007 Oct 12;8:26.

PMID:
17935622
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk